Compare Crispr Therapeutics AG (CRSP) vs Otis Worldwide Corp (OTIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Otis Worldwide Corp — how do they compare? Crispr Therapeutics AG trades at $54.25 (market cap $5.23B), while Otis Worldwide Corp trades at $73.85 (market cap $27.80B). The key difference: Otis Worldwide Corp is far larger — about 5.3× Crispr Therapeutics AG's market cap, and Otis Worldwide Corp pays a 2.41% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | OTIS | |
|---|---|---|
Market Cap | $5.23B | $27.80B |
Sector | Health | Industrials |
52-Week High | $76.78 | $93.62 |
52-Week Low | $44.34 | $69.34 |
Enterprise Value | $3.65B | $35.84B |
Dividend Yield | — | 2.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.83, up 0.6% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a Q2 2026 EPS beat with a loss of $0.94 versus an expected $1.19 loss, driven by surging CASGEVY sales. However, financials show deep losses, with a net income margin of -4,101.26% in 2025 and negative operating cash flow, though financing activities provided liquidity.
The outlook is mixed: strong analyst consensus (57.9% buy ratings) and a $82.67 price target reflect optimism around CASGEVY growth and pipeline catalysts, but high valuation (P/S of 466.05) and persistent cash burn pose significant risks. Investment appeal hinges on successful clinical advancements and path to profitability.
Otis Worldwide (OTIS) trades at $73.58, up 0.97% on the day, with a neutral technical signal. The company reported mixed Q2 2026 results, beating revenue estimates but missing EPS expectations and cutting full-year profit guidance due to margin pressures. Strong service segment growth, particularly in modernization, contrasts with weak new equipment demand. Analyst consensus is divided with a $92.50 price target, suggesting significant upside from current levels.
The outlook balances service-driven revenue momentum against near-term margin headwinds. Investment opportunity lies in Otis's defensive service business and global market leadership, but risks include execution on margin improvement, China exposure, and competitive pressures. Cash flow volatility and high debt levels require monitoring for sustained shareholder value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →
